局部阿米替林和氯胺酮在神经性疼痛综合症:一个开放研究。
文章的细节
-
引用
复制到剪贴板 -
林奇我,克拉克AJ,沙利文Sawynok J,乔丹
局部阿米替林和氯胺酮在神经性疼痛综合症:一个开放研究。
J痛苦。2005年10月,6 (10):644 - 9。
- PubMed ID
-
16202956 (在PubMed]
- 文摘
-
二十8名被耐火材料,中度到重度的周围神经性疼痛参与开放标签前瞻性试验研究认为镇痛效果,病人满意度,和安全的局部阿米替林2% /氯胺酮1%奶油。结果评价包括11个数字疼痛强度评定量表(NRS-PI), 5点满意度量表,血液化学屏幕,药物和代谢物水平,验尿,心电图(ECG),体检。不良事件监测。21岁受试者完成了试验。在6个月时,受试者报告平均长期的痛苦减少了34%(标准差(SD) = 37%);5科目(25%)达到50%或更大的减少疼痛和疼痛减少1主题(5%)达到了100%。在12个月内,平均减少疼痛是37% (SD = 40%);7个主题减轻疼痛(40%)达到50%或更高。在研究结束时,89%的受试者认为满意为3/5或更大的自由和2个科目(10%)疼痛。最小的不良事件报告,没有严重的药物相关的不良事件。 Blood levels revealed minimal systemic absorption. In conclusion, topical 2% amitriptyline/ 1% ketamine cream was associated with long-term reduction (6-12 months) in perceived pain, moderate to complete satisfaction, and was well tolerated in treatment of neuropathic pain. There was no significant systemic absorption of amitriptyline or ketamine. PERSPECTIVE: This study demonstrates that topical 2% amitriptyline/1% ketamine, given over 6-12 months, is associated with long-term perceived analgesic effectiveness in treatment of neuropathic pain. Antidepressants and ketamine both produce multiple pharmacologic effects that may contribute to peripheral analgesia; such actions include block of peripheral N-methyl-D-aspartate receptors, local anesthetic properties, and interactions with adenosine systems.
DrugBank数据引用了这篇文章
- 药物